A Phase I/II Study of Pomalidomide and Dexamethasone With Growth Factor Support in Patients With Relapsed/Refractory Multiple Myeloma

Trial Profile

A Phase I/II Study of Pomalidomide and Dexamethasone With Growth Factor Support in Patients With Relapsed/Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Pomalidomide (Primary) ; Dexamethasone; Filgrastim
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 05 May 2014 New source identified and integrated (M.D. Anderson Cancer Center; 2013-0018).
    • 05 Mar 2014 Planned End Date changed from 1 Feb 2021 to 1 Mar 2021 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top